Kiromic BioPharma announces the transition of its CFO
HOUSTON – (COMMERCIAL THREAD) – Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a preclinical biotechnology company using its owner DIAMOND® Artificial Intelligence (“AI”) Platform to Enhance Drug Discovery and Development with Therapeutic Focus on Immuno-Oncology, Announces Appointment of Daniel Clark as Interim Chief Financial Officer (“CFO”) , as of September 30, 2021.
Former Kiromic CFO, Mr. Tony Tontat, resigned on September 29, 2021, effective immediately.
“It is natural to appoint Dan Clark as Interim Chief Financial Officer, having served as both Kiromic’s Vice President of Financial Operations and our Corporate Controller. Dan has a strong sense of finances and references, two critically important qualifications that I and the rest of our management team can attest to. We are delighted to appoint him to this position, ”said Maurizio Chiriva Internati, DBSc, PhDs, CEO, President and Founder of Kiromic BioPharma.
“I have enjoyed supporting our management team and board of directors since joining the company, and I am delighted to continue working alongside the team and overseeing the operation of the financial organization and Kiromic accountant. In addition, I look forward to facilitating the smooth transition of the permanent CFO whenever he is identified, ”said Mr. Clark.
Mr. Clark joined Kiromic in February 2020 and served as the company’s management controller until September 2021, when he was promoted to Vice President – Financial Operations. Prior to joining the firm, Mr. Clark was a Director at The Siegfried Group, a national accounting services firm, from June 2018 to February 2020. Prior to his employment with The Siegfried Group, Mr. Clark served as a consultant Principal – Office of the Chief Financial Officer. Solutions for FTI Consulting, a global financial consulting firm, from January 2017 to May 2018. Previously, Mr. Clark was Senior Associate – Audit at KPMG US, a member of the global accounting firm Big Four KPMG, from August 2011 to June 2015. Mr. Clark holds an MBA from Texas A&M University, Mays School of Business and a Bachelor of Science in Business Administration with specialization in Accounting from the University of Richmond, Robins School of Business. Mr. Clark is a Chartered Accountant in the State of Texas.
About Kiromic BioPharma
Kiromic BioPharma, Inc. is an AI-driven end-to-end CAR-T and gene therapy company developing the first multi-indication allogeneic CAR-T cell therapy, which harnesses the natural power of Gamma Delta T cells to target solid cancers.
Kiromic BioPharma, Inc. is focused on the discovery, development and commercialization of novel immuno-oncology applications through its strong product portfolio. The development of the pipeline is based on the Company’s proprietary target discovery engine called “DIAMOND”. Kiromic’s DIAMOND is the big data science that responds to target identification, dramatically compressing man-years and billions of dollars of drug development to develop a living drug. The Company has offices in Houston, Texas. For more information, please visit the company’s website at www.kirmic.com.